Somewhat Positive Media Coverage Somewhat Unlikely to Affect Laboratory Corp. of America (LH) Stock Price

Media stories about Laboratory Corp. of America (NYSE:LH) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Laboratory Corp. of America earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 46.3034713258049 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Several equities research analysts recently issued reports on LH shares. Zacks Investment Research lowered shares of Laboratory Corp. of America from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Barclays lifted their price target on shares of Laboratory Corp. of America from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, February 26th. They noted that the move was a valuation call. Mizuho set a $178.00 price target on shares of Laboratory Corp. of America and gave the company a “hold” rating in a report on Wednesday, January 24th. ValuEngine raised shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Jefferies Group reaffirmed a “hold” rating and set a $176.00 price target on shares of Laboratory Corp. of America in a report on Tuesday, March 6th. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $189.19.



NYSE:LH traded down $0.05 during mid-day trading on Tuesday, hitting $166.45. 394,035 shares of the company’s stock were exchanged, compared to its average volume of 669,513. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.31 and a quick ratio of 1.20. Laboratory Corp. of America has a fifty-two week low of $134.19 and a fifty-two week high of $181.71. The company has a market cap of $16,795.16, a PE ratio of 17.35, a P/E/G ratio of 1.41 and a beta of 0.94.

Laboratory Corp. of America (NYSE:LH) last posted its earnings results on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, topping the consensus estimate of $2.38 by $0.07. The business had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.70 billion. Laboratory Corp. of America had a net margin of 12.15% and a return on equity of 16.30%. The firm’s revenue was up 13.2% compared to the same quarter last year. During the same period last year, the company earned $2.15 EPS. equities research analysts expect that Laboratory Corp. of America will post 11.55 EPS for the current year.

In related news, Director Adam H. Schechter sold 1,263 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $169.29, for a total transaction of $213,813.27. Following the transaction, the director now owns 7,297 shares in the company, valued at approximately $1,235,309.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Glenn A. Eisenberg sold 8,400 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $167.36, for a total transaction of $1,405,824.00. Following the transaction, the chief financial officer now owns 15,931 shares in the company, valued at approximately $2,666,212.16. The disclosure for this sale can be found here. Insiders sold a total of 59,630 shares of company stock worth $9,851,701 in the last 90 days. Corporate insiders own 0.73% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Laboratory Corp. of America (LH) Stock Price” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://stocknewstimes.com/2018/04/17/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-laboratory-corp-of-america-lh-share-price.html.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply